Drugs / PX-478
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00522652 | Aug 2007 → May 2010 | cancer, lymphoma | Cascadian Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PX-478 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00522652 ↗ |
| Action | Inhibit | “PX-478, an inhibitor of hypoxia-inducible factor-1alpha” PMID 18729192 ↗ Nov 2008 |
| Modality | Protein / enzyme biologic | — CHEMBL4117516 ↗ |
| Route | Oral | “Oral formulation” NCT00522652 ↗ |
| Target | HIF1A | “PX-478, an inhibitor of hypoxia-inducible factor-1alpha” PMID 18729192 ↗ Nov 2008 |